The annual International Association for the Protection of IP (AIPPI) conference in Helsinki, Finland, assessed the potential problems for pharmaceutical companies trying to brand their medicinal products.
During a workshop on September 6, one issue discussed was the difference between a trademark signifying a branded product and an international nonproprietary name (INN), which signifies a medical effect.
Examples of registered INNs include -olol for beta blockers (eg, atenolol) and -oxetine for fluoxetine derivatives, a group of antidepressants.
Raffaella Mattivelli, INN programme manager at the World Health Organization (WHO), said: “We have developed a resolution to ensure the INN is prominently displayed on the box of products and is easy to understand.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
AIPPI, pharmaceuticals, trademarks, brands, INN
